

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Hepatology

ESPS manuscript NO: 15661

Title: Hepatitis B reactivation in the setting of chemotherapy and immunosuppression – prevention is better than cure

Reviewer's code: 00073008

Reviewer's country: Poland

Science editor: Fang-Fang Ji

Date sent for review: 2014-12-04 08:26

Date reviewed: 2015-01-05 05:38

| CLASSIFICATION | LANGUAGE EVALUATION | RECOMMENDATION | CONCLUSION |
|--|---|-------------------------------------|--|
| <input type="checkbox"/> Grade A: Excellent | <input type="checkbox"/> Grade A: Priority publishing | Google Search: | <input checked="" type="checkbox"/> Accept |
| <input checked="" type="checkbox"/> Grade B: Very good | <input checked="" type="checkbox"/> Grade B: Minor language polishing | <input type="checkbox"/> Existing | <input type="checkbox"/> High priority for publication |
| <input type="checkbox"/> Grade C: Good | <input type="checkbox"/> Grade C: A great deal of language polishing | <input type="checkbox"/> No records | <input type="checkbox"/> Rejection |
| <input type="checkbox"/> Grade D: Fair | <input type="checkbox"/> Grade D: Rejected | <input type="checkbox"/> Existing | <input type="checkbox"/> Minor revision |
| <input type="checkbox"/> Grade E: Poor | | <input type="checkbox"/> No records | <input type="checkbox"/> Major revision |

COMMENTS TO AUTHORS

Comments to the manuscript: The presented article is written in fine English and explains an interesting medical problem. The articles selected for the review present current knowledge and have been selected very carefully. The problem of HBV reactivation in patients underwent immunosuppressive therapy is still being investigated. The introduction of the new classes of immunosuppressive agents in malignant tumors and autoimmune disorders revealed a difficult clinical problem of the selection of adequate antiviral therapy. The pre-emptive antiviral therapy in anti-HBc reactive subjects is still controversial. In this article the author presents commonly accepted therapeutic strategies and explains some doubts. The data presented in the article "Hepatitis B reactivation in the setting of chemotherapy and immunosuppression – prevention is better than cure" are valuable, but the reviewer has found some minor defects: 1. In the paragraph 2: lack of references for the explanation of both HBV mechanisms of hepatocytes damage. 2. The references in the text should be corrected to WJG instructions to authors 3. HBV genotype in Mediterranean is D; genotypes B and C are rare in Caucasians.

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Hepatology

ESPS manuscript NO: 15661

Title: Hepatitis B reactivation in the setting of chemotherapy and immunosuppression – prevention is better than cure

Reviewer's code: 00052899

Reviewer's country: China

Science editor: Fang-Fang Ji

Date sent for review: 2014-12-04 08:26

Date reviewed: 2015-01-04 21:04

| CLASSIFICATION | LANGUAGE EVALUATION | RECOMMENDATION | CONCLUSION |
|---|--|-------------------------------------|--|
| <input type="checkbox"/> Grade A: Excellent | <input type="checkbox"/> Grade A: Priority publishing | Google Search: | <input type="checkbox"/> Accept |
| <input type="checkbox"/> Grade B: Very good | <input type="checkbox"/> Grade B: Minor language polishing | <input type="checkbox"/> Existing | <input type="checkbox"/> High priority for publication |
| <input type="checkbox"/> Grade C: Good | <input type="checkbox"/> Grade C: A great deal of language polishing | <input type="checkbox"/> No records | <input type="checkbox"/> Rejection |
| <input type="checkbox"/> Grade D: Fair | <input type="checkbox"/> Grade D: Rejected | <input type="checkbox"/> Existing | <input type="checkbox"/> Minor revision |
| <input type="checkbox"/> Grade E: Poor | | <input type="checkbox"/> No records | <input type="checkbox"/> Major revision |

COMMENTS TO AUTHORS

In this review, the author discussed the definition, risk factors, management, prevention and monitoring of hepatitis B reactivation (HBVr) in the setting of chemotherapy and immunosuppression in a systematic manner. Recommendations regarding screening, monitoring and the application of antiviral prophylaxis were outlined with reference to current international associations' guidelines in the form of table. The most concerned clinical problems on the topic of HBVr during chemotherapy and immunosuppression were also reviewed and discussed in detail. However, there are still several issues that should be corrected. 1. In table 2, risk estimates of HBVr should be evaluated on the basis of dividing patients into HBsAg positive and HBsAg negative/anti-HBc positive, as summarized in table 2 in American Gastroenterological Association Institute Technical Review on Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug Therapy. 2. The grading of severity degree of HBVr is recommended to be introduced in the third part "Definitions of HBV reactivation and associated clinical endpoints". 3. The serial number of some subheadings in the manuscript was incorrect and should be revised. 4. There are several typographical errors.